Tags: ovarian cancer | chemotherapy | intraperitoneal

Ovarian Cancer Treatment Underused

By
Friday, 28 Apr 2017 04:22 PM Current | Bio | Archive

Chemotherapy delivered directly into the abdomen significantly improves survival among women with advanced ovarian cancer, a new study finds.

However, fewer than half of U.S. patients who could benefit from this treatment -— called intraperitoneal chemotherapy — are receiving it, according to Dana-Farber/Brigham and Women’s Cancer Center researchers.

According to the study, 81 percent of women who received the dual therapy were alive three years after treatment, compared with 71 percent of those who received IV chemotherapy alone.

Yet only 41 percent of the patients who were deemed to be suitable candidates actually received the dual therapy, the team reported.

The study was published in the Journal of Clinical Oncology.

© 2017 NewsmaxHealth. All rights reserved.

 
1Like our page
2Share
Dr-Schwartz
According to the study, 81 percent of women who received the dual therapy were alive three years after treatment, compared with 71 percent of those who received IV chemotherapy alone.
ovarian cancer, chemotherapy, intraperitoneal
109
2017-22-28
Friday, 28 Apr 2017 04:22 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved